Preclinical
DITPA / Petratos: new preclinical readout reports neuroprotection and myelin repair in EAE
Steven Petratos's team reported that daily oral DITPA limited neurological deterioration, increased oligodendrocyte survival, reduced myelin and axonal injury and improved remyelination markers in EAE.
What this means clinically
This is a serious translational programme with active preclinical development, but no publicly registered MS clinical trial. Mouse results are not evidence of clinical benefit.
Source quality: Preliminary • preprint, peer review not completed